Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00194987 · ClinicalTrials.gov registry record · Phase 2
A Trial of Antenatal Treatment of Alloimmune Thrombocytopenia
A Phase 2 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
NCT00194987 is a Phase 2 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 102 participants.
The verdict
NCT00194987, a Phase 2 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
Study Summary
The purposes of this study are to provide medical management by giving treatment to the mother that will bring up the fetal platelet count and to minimize the number of invasive procedures to the fetus (which may result in serious fetal injuries).
Interventions
- DRUG prednisone
- DRUG IVIG (Intravenous Immunoglobulin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2001-04 |
| Est. Completion | 2015-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00194987
The ClinicalTrials.gov registry entry for NCT00194987 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which prednisone is the first listed.
NCT00194987 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00194987 about?
NCT00194987 is a clinical study titled "A Trial of Antenatal Treatment of Alloimmune Thrombocytopenia". The purposes of this study are to provide medical management by giving treatment to the mother that will bring up the fetal platelet count and to minimize the number of invasive procedures to the fetus (which may result in serious fetal injuries).
What is the current status of trial NCT00194987?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2001-04. Estimated completion is 2015-06-30.
What interventions are being tested in trial NCT00194987?
The interventions under investigation include: prednisone (DRUG), IVIG (Intravenous Immunoglobulin) (DRUG).
Who is sponsoring clinical trial NCT00194987?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.